475 results about "Animal origin" patented technology

Recombinant Factor VIII can be produced in relatively large quantities on a continuous basis from mammalian cells in the absence of any animal-derived proteins such as albumin by culturing the cells in a protein free medium supplemented with polyol copolymers, preferably in the presence of trace metals such as copper. In very preferred embodiments, the medium includes a polyglycol known as Pluronic F-68, copper sulfate, ferrous sulfate/EDTA complex, and salts of trace metals such as manganese, molybdenum, silicon, lithium and chromium. With an alternative medium which included trace copper ions alone (without polyol copolymers) we were also able to enhance the productivity of Factor VIII in recombinant cells such as BHK cells that are genetically engineered to express Factor VIII.

The invention relates to a hydrotreating method (HDT) using two plants working under different operating conditions with an intermediate stripping for co-treating a mixture made up of oils of vegetable or animal origin and petroleum cuts (gas oil cuts (GO) and middle distillates) in order to produce gas oil fuel bases meeting specifications. The first plant (HDT1) is more particularly dedicated to the reactions concerning oils of vegetable or animal origin in comixture while pretreating the hydrocarbon feed, whereas the second plant (HDS2) works under more severe conditions to obtain diesel fuel according to standards, in particular in terms of effluent sulfur content, density and cold properties. The process economy, the activity and the stability of the catalyst of the second plant are greatly improved by the intermediate stripping.

A hydrotreating method uses two catalyst beds with the introduction, on the last catalyst bed, of oils of animal or vegetable origin for co-treating a mixture made up of oils of vegetable or animal origin and of petroleum cuts (gas oil cuts (GO) and middle distillates) in order to produce gas oil effluents meeting specifications with an improved cetane number. The first catalyst bed is dedicated to only the deep desulfurization reactions (HDS1) of a petroleum type feed. The effluents of the first catalyst bed having an effluent sulfur content below or equal to 50 mg/kg are separated into two streams. The first stream, which is predominant, is sent to the gas oil pool. The second stream is mixed with oils of vegetable or animal origin. The resultant oil-petroleum cut mixture is then subjected to a milder hydrotreatment (HDT2). The effluents obtained at the outlet of the second catalyst bed can optionally be mixed with the predominant stream from the first bed. The process economy, the tolerance to the specifications relative to oils of animal or vegetable origin and the quality of the products obtained are thus greatly improved.

A method for texturing the surface of a breast implant includes the step of partially impregnating a silicone outer surface of the implant with particles of a biologically active material such as acellular dermis of human or animal origin impregnated with hyaluronic acid. The biologically active material promotes tissue ingrowth into a plurality of cavities filled with a biologically active material.

A method for texturing the surface of a breast implant includes the step of partially impregnating a silicone outer surface of the implant with particles of a biologically active material such as acellular dermis of human or animal origin impregnated with hyaluronic acid. The biologically active material promotes tissue ingrowth into a plurality of cavities filled with a biologically active material.

The present invention comprises the discovery and development of an effective cryoprotectant composition, without containing skim milk or any other animal-derived compounds, to achieve long-term stability of freeze-dried lactic acid bacteria (LAB), at different temperatures, whereby the retention of viability of the freeze-dried LAB after 6 months of storage, preferably after 9 months of storage, more preferably after 12 months of storage is more than 50%. The invention is in the field of producing freeze dried bacteria, in particular Lactic acid bacteria. More in particular, the invention relates to the use of a novel combination of cryoprotectants for increasing the viability of bacteria after freeze drying, improving the texture of the lyofilized cake for easy grinding and improving the long term stability of the freeze dried bacteria at different temperature conditions. The invention further relates to such freeze dried bacteria for use in food industry or in human or animal health applications. More in particular, the invention relates to the increased viability and long-term storage of recombinant bacteria capable of expressing heterologous proteins or peptides and administered to humans or animals for therapeutic or vaccination purposes.

A method for preparing a scaffold material for use in the prosthesis therapy is disclosed. The method comprises (a) lyophilizing a segment of native soft tissue of mammalian origin, heating the lyophilized tissue at a temperature of 100-200° C., and incubating the tissue with elastase to selectively remove elastin leaving the extracellular components mainly comprised of collagen.

The invention discloses a special physiological regulator for maternal animals, and a preparation method thereof, and belongs to the field of feed additive. A technical scheme of the physiological regulator comprises: carrying out crushing and screening for dandelion, leonurus, licorice root and angelica; adding soybean meal and/or wheat bran; adding water to carry out immersing; adjusting pH value of the resulting mixture; carrying out a sterilization; inoculating probiotics to carry out a fermentation after cooling, followed by stoving after completing the fermentation to obtain the physiological regulator. With the prepared physiological regulator for the maternal animals, immunity and disease resistance of the maternal animals are raised, incidence rate of genital system infection is effectively reduced, feed inversion rate is increased, mammogenesis is improved, milk yield is raised, incidence rate of mammitis is reduced, and milk quality is improved. The physiological regulator has characteristics of quick onset, stable and reliable effect, no toxic and side-effect, no pollution, no residue, and no drug resistance generating, and meets requirements of safe feed additive and assurance of foods of animal origin. In addition, the physiological regulator for the maternal animals can be adopted as a veterinary drug through raising using dosage of the physiological regulator, and provides a substantial curative effect for prevention and cure of the mammitis.

Naturally occurring lipids of vegetable and animal origin are broken into smaller molecules, and used as dewatering aids. The process of breaking the molecules include transesterification, interesterification, and saponification followed by acidulation. The modified lipid molecules can adsorb on the surface of the particles to be dewatered and greatly enhance their hydrophobicity, which will help increase the rate of dewatering and hence reduce cake moisture. The modified lipids are more effective dewatering aids than the naturally occurring unmodified lipids, possibly because they can more readily form close-packed monolayers of hydrophobes on the surface of the particles.

A method for displaying scanned ultrasound images of tissue employs an apparatus including an ultrasound probe mounted to a mechanical head. A three-dimensional positioning system mounts the head for positioning the probe in proximate orthogonal relation to the tissue. A computer controls the three-dimensional positioning system thereby moving the probe during a scan. The probe transmits high frequency ultrasound waves whose nominal frequency is included within the range from 30 to 100 MHz and with a large pass band, adapted to frequencies reflected by the tissue. The beams of ultrasound transmission are focused in a given zone of the tissue over a vertical penetration distance of between 20 and 30 mm. Reflected signals are acquired and processed for display.

This invention relates to an automatic pod-conveyor and brewer assembly for fresh hot beverage. The brewer sub-assembly (100) includes a pneumatic cylinder (110) with its piston rod (120) fitted to a brewer plunger (130). An injection nozzle (180) is detachably fixed from underneath to the brewer base (195) with its conical tip protruding into the brewer chamber (150). The single serving pod (160) is a receptacle (510) containing the brewing, infusible or other material (520), covered and sealed with a porous membrane (530). The injection nozzle (180) injects hot pressurized water, received through its interior from a suitable water heating system, into a single serving pod (160) placed within the brewer sub-assembly (100), and the brewed beverage flows out to a dispensing cup through a liquor outlet port (190) in the brewer base (195). The pneumatic cylinder (110) is operated by air solenoid valve (165) with compressed air from a compressed air storage tank (170). The pod-conveyor sub-assembly (200) includes a pod conveyor (210) which, by its rotational movement in a horizontal plane, conveys the pod (160) to the brewer sub-assembly (100) from chutes (280, 290). The pod-conveyor (210) is operated by a pusher motor (250) in co-operation with a pusher gear (230) fitted to the integral shaft (215) of the pod-conveyor (210). The assembly can be used to prepare hot beverage of a wide variety of brewing, infusible or other materials like tea, coffee, materials of plant origin such as floral pieces like Jasmine flowers, vegetable pieces like carrots, onions, materials of animal origin such as honey or other suitable beverage powder/material which can be placed in the single serving pod (160) of the assembly.

The invention relates to an animal origin-free low-protein culture medium suitable for animal cell product production, comprising 24 basic metabolism nutrients, 11 vitamins, 3 transferrin substitute compounds, 5 lipid compounds, 2 nucleic acid compounds, 4 hormones and growth factors, 3 antioxidants, 1 shear-resistant protective agent, 1 pH indicator, 2 pH buffers, 9 other inorganic salts, soy hydrolysates adopted to substitute animal origin component, and composition of ferrous sulfate, ferric nitrate and EDTA-2Na adopted to substitute transferrin. The culture medium can be made by dissolving the aforementioned components in triply distilled water. The positive effects of the culture medium are as follows: the culture medium contains no animal origin component, the total protein content is lower than 10mg/L, which helps separate and purify products and is suitable for production of recombinant protein medicaments; the culture medium supports normal growth and long-term subculturing of animal cells; the culture medium can be used without adaptation, is easily prepared and is suitable for massive production of animal cell products.

The present invention relates to the use of one or more natural or modified oxygen carriers, devoid of plasma or cellular membrane constituents, for the production of an agent for the external treatment of open wounds, particularly chronic wounds. Hemoglobin or myoglobin of human or animal origin are suitable as oxygen carriers. The oxygen carriers can also preferably be modified. Suitable modifications are cross-linking, reaction with polyalkylene oxides, chemically reactive or chemically non-reactive effectors, or combinations. The agent is applied to the wound area particularly by means of spraying on an aqueous solution containing the oxygen carrier(s). The oxygen carriers can be used in particularly effective manner in the case of chronic wounds resulting from tissue degeneration, particularly diabetic tissue degeneration.

The invention provides a humanized PD-L1 tumor cell line MC-38-hPD-L1, a builtanimal tumor model with the same and a method for constructing the humanized PD-L1 tumor cell line. The method particularly includes knocking out animal-origin PD-L1 by the aid of CRISPR-CAS9; carrying out amplification and cultivation to obtain knocked-out cell banks; extracting DNA (deoxyribonucleic acid) and carrying out PCR (polymerase chain reaction) amplification; recycling and cloning amplification products; carrying out over-expression on human-origin PD-L1 in MC-38 cell lines of mPD-L1 KO by the aid of lentivirus systems; packaging lentivirus and screening Puromycin to obtain the humanized MC-38 cell line of PD-L1. The humanized PD-L1 tumor cell line, the animal tumor model and the method have the advantages that as shown by results, high killing efficiency and multiplication capacity are obviously presented by tumor infiltration CD8 T lymphocytes after antibody treatment is carried out, tumor infiltration Treg cells can be obviously inhibited after antibody treatment is carried out, and accordingly the method is proved to be effective and feasible from the aspect of molecular mechanisms.

A palatable, edible soft chewable medication vehicle for delivery of a pharmaceutically acceptable active ingredient, such as a drug, to an animal or human subject. The edible soft chews contain only food grade or better inactive ingredients, and preferably do not contain ingredients of animal origin. Processes for manufacturing the edible soft chews do not require the use of heat or the addition of water during mixing of active and inactive ingredients, provide stable concentrations of the active ingredient, and produce chews of consistent weight and texture.

An animal-derived lipid is disclosed that is useful as a carrying agent for anti-microbial formulations. Pharmaceutical and other preparations including Emu Oil are also described as profoundly useful components in anti-bacterial, anti-fungal, and anti-viral treatments. This lipid material is extracted from the Emu (Dromais Novae-Hollandiae), an indigenous bird of Australia and New Zealand. The present invention also discloses therapeutic compositions comprising Emu Oil in combination with an extracellular product of Bacillus coagulans or Pseudomonas lindbergii strain, comprising a supernatant or filtrate of said culture suitable for topical application to the skin or mucosal membranes of a mammal, which are utilized to inhibit the growth of bacterium, yeast, fungi, virus, and combinations thereof. Additionally, the aforementioned therapeutic composition may also include an anti-microbial, anti-mycotic, and/or anti-viral agent. The present invention also discloses methods of treatment and therapeutic systems for inhibiting the growth of bacterium, yeast, fungi, virus, and combinations thereof, by topical application of therapeutic compositions comprising Emu Oil in combination with an extracellular product of Bacillus coagulans or Pseudomonas lindbergii strain suitable for topical application to the skin or mucosal membranes of a mammal. Similarly, the aforementioned method may also employ a therapeutic composition additionally containing an anti-microbial, anti-mycotic, and/or anti-viral agent.

The disclosure relates to an animal feed or feed ingredient containing from about 0.01% to 1.0% DHA, wherein all, or substantially all of the DHA comes from material that is of non-animal origin and the use of microbially-derived DHA at these low levels provides sufficient DHA for the optimal neurological development of the animal.